Two Sigma Advisers LP Grows Stock Position in Vigil Neuroscience, Inc. (NASDAQ:VIGL)

Two Sigma Advisers LP boosted its position in shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) by 243.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 69,100 shares of the company's stock after acquiring an additional 49,000 shares during the quarter. Two Sigma Advisers LP owned 0.17% of Vigil Neuroscience worth $117,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of VIGL. abrdn plc increased its holdings in Vigil Neuroscience by 124.9% in the 4th quarter. abrdn plc now owns 528,472 shares of the company's stock worth $898,000 after acquiring an additional 293,461 shares in the last quarter. Cubist Systematic Strategies LLC increased its holdings in Vigil Neuroscience by 53.0% in the 4th quarter. Cubist Systematic Strategies LLC now owns 24,120 shares of the company's stock worth $41,000 after acquiring an additional 8,358 shares in the last quarter. Barclays PLC increased its holdings in Vigil Neuroscience by 43.6% in the 4th quarter. Barclays PLC now owns 64,049 shares of the company's stock worth $109,000 after acquiring an additional 19,436 shares in the last quarter. Jane Street Group LLC purchased a new stake in Vigil Neuroscience in the 4th quarter worth approximately $83,000. Finally, Millennium Management LLC increased its holdings in Vigil Neuroscience by 23.3% in the 4th quarter. Millennium Management LLC now owns 343,814 shares of the company's stock worth $584,000 after acquiring an additional 65,058 shares in the last quarter. Hedge funds and other institutional investors own 83.64% of the company's stock.

Vigil Neuroscience Price Performance

Shares of NASDAQ VIGL traded down $0.02 during midday trading on Wednesday, reaching $7.86. 2,435,545 shares of the stock traded hands, compared to its average volume of 692,474. The stock has a market capitalization of $366.84 million, a PE ratio of -3.82 and a beta of 3.43. Vigil Neuroscience, Inc. has a one year low of $1.31 and a one year high of $7.95. The company's 50 day moving average is $3.78 and its 200 day moving average is $2.71.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported ($0.49) EPS for the quarter, beating analysts' consensus estimates of ($0.53) by $0.04. As a group, equities analysts forecast that Vigil Neuroscience, Inc. will post -2.07 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on VIGL. William Blair lowered shares of Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 22nd. Jefferies Financial Group downgraded Vigil Neuroscience to a "hold" rating in a research note on Thursday, May 22nd. Wedbush downgraded Vigil Neuroscience from a "strong-buy" rating to a "hold" rating and dropped their price target for the stock from $13.00 to $8.00 in a research note on Thursday, May 22nd. Citizens Jmp downgraded Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a research note on Thursday, May 22nd. Finally, JMP Securities restated a "market perform" rating on shares of Vigil Neuroscience in a research note on Thursday, May 22nd. Ten analysts have rated the stock with a hold rating, According to MarketBeat, Vigil Neuroscience has an average rating of "Hold" and an average price target of $10.80.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.